Form 8-K Valeant Pharmaceuticals For: Feb 28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Valeant Pharma (VRX) Setting Stage for Potential Capital Raise in 2018 - Evercore ISI's Raffat
February 28, 2018 9:50 AM ESTEvercore ISI analyst Umer Raffatt thinks Valeant Pharma (NYSE: VRX) could tap the capital market this year.
He notes while Valeant gave no clear answer on whether Valeant will look to raise capital near term and emphasized that there... More
